• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adding sargramostim to ipilimumab may improve survival in advanced melanoma

byJeffrey CohenandPriyanka Vedak
November 5, 2014
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding sargramostim to ipilimumab for advanced melanoma resulted in improvement in overall survival and fewer adverse events when compared to ipilimumab alone.

2. Adding sargramostim to ipilimumab for advanced melanoma demonstrated no improvement in progression free survival.

Evidence Rating Level: 2 (Good)       

Study Rundown: Melanoma is a leading cause of cancer incidence and mortality in the United States. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF) have both been used to treat metastatic melanoma. This phase II randomized trial examined the effect of adding sargramostim to ipilimumab on overall and progression free survival in individuals with advanced melanoma, defined as unresectable stage III or IV disease. While the addition of sargramostim to ipilimumab resulted in an increase in overall survival and fewer adverse events, it did not improve progression free survival.

Strengths of this study include its randomized design and careful use of inclusion and exclusion criteria. However, results may have been influenced by bias due to the lack of investigator blinding and are limited by the short follow-up period. Nevertheless, this study ultimately demonstrated the potential benefits of combined ipilimumab/sargramostim therapy for the treatment of advanced melanoma and emphasizes the need for a larger randomized controlled trial to more fully understand the benefits of this treatment regimen.

Click to read the study, published today in JAMA

Relevant Reading: Improved survival with ipilimumab in patients with metastatic melanoma.

RELATED REPORTS

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

In-Depth [randomized controlled trial]: This study randomized 425 individuals with advanced melanoma (i.e., unresectable stage III or IV disease) to receive ipilimumab and sargramostim or ipilimumab alone to determine if adding sargramostim to ipilimumab improves overall or progression free survival. The participants were predominantly male and Caucasian and the ages of participants ranged from 21-89 years. The median follow-up time was 13.3 months (range 0.03-19.9 months). The addition of sargramostim to ipilimumab resulted in an overall survival benefit (log-rank p=0.01), but not a progression free survival benefit (log-rank p=0.37). The addition of sargramostim to ipilimumab also demonstrated fewer adverse effects than ipilimumab alone, notably with regards to colonic perforation.

More from this author: Ambulances equipped for thrombolysis allow for more rapid stroke treatment, Stem cell transplant may be effective in sickle cell disease, Vitamin D supplementation in the ICU does not improve outcomes [VITdAL-ICU trial], Antibiotic use prevalent among hospitalized patients in the US, Frozen fecal transplant effective for Clostridium difficile infection

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: ipilimumabmelanomasargramostim
Previous Post

Non-obstructive coronary artery disease linked with increased heart attacks, death

Next Post

Modified embryonic stem cells may prolong survival of surgical grafts

RelatedReports

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 22, 2022
Choosing Wisely campaign releases recommendations in newborn medicine
Oncology

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 28, 2022
#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma
StudyGraphics

#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

November 17, 2022
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

October 20, 2022
Next Post
Modified embryonic stem cells may prolong survival of surgical grafts

Modified embryonic stem cells may prolong survival of surgical grafts

PD/Army

Cost-effectiveness of lung cancer screening with CT estimated

Double-opposing Z-plasty may improve cleft palate outcomes

Double-opposing Z-plasty may improve cleft palate outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options